whatshot

ARWR   $20.5  -3.21% Market Closed After Close 20.49 -0.05%

Arrowhead Pharmaceuticals Inc
show_chart Advanced Chart of ARWR
Last Events:

2023-11-30 The hottest instrument.

2023-08-06 Trend pattern changed from канал to расходящийся клин с наклоном вверх.

2023-08-03 Trend pattern changed from нисходящий треугольник to канал.

2023-08-03 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-02 Signal in MACD changed from bullish weakening to bearish. Oscillator MACD is in the negative territory it's higher than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-02 Signal in RSI changed from bullish weakening to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-08-02 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-02 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

Current temperature: 0.00
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 30.31
High with % probability:
Analyst Recommendations:
Number of estimates 14
Target Price Mean 47.29
Mean unverified/preliminary 47.29 / 47.29
Target Price Low / High 20.00 / 71.00
Median / STD DEV 50.50 / 18.18
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy Buy Buy
rsi ActivelyBuy Sell Sell
macd None None None
stoch ActivelyBuy None None
ma20 Sell Buy None
ma50 ActivelyBuy None None
ma100 ActivelyBuy ActivelyBuy ActivelyBuy
Candlestick PatternOct. 10, 2024 Three Gaps Down - pattern is a made up of four black candlesticks. Pattern appears on a uptrend and consists of three consecutive days each gapping lower on the open. Considered to be a bullish reversal pattern.
ISIN US04280A1007
ceo Dr. Christopher R. Anzalone Ph.D.
Website https://arrowheadpharma.com
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.